Holen Sie sich die Stockscreener-App
264.21
0.40%
-1.05
Schlusskurs vom Vortag:
$265.26
Offen:
$265.11
24-Stunden-Volumen:
211.85K
Relative Volume:
0.60
Marktkapitalisierung:
$5.81B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-9.6674
EPS:
-27.33
Netto-Cashflow:
$223.75M
1W Leistung:
-7.16%
1M Leistung:
+5.38%
6M Leistung:
-22.77%
1J Leistung:
-19.54%
1-Tages-Spanne:
$262.05
$266.20
1-Wochen-Bereich:
$261.65
$285.58
52-Wochen-Spanne:
$211.43
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Vergleichen Sie BIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
264.21 | 7.15B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
134.28 | 227.88B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.14 | 152.55B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
377.58 | 143.34B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.88 | 114.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.35 | 46.11B | 5.69B | 4.14B | 577.90M | 6.96 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause - Seeking Alpha
Enzyme Linked Immunosorbent Assay Market: Analysis of Size, - openPR.com
Hemoglobin A1c Testing Devices Market to Grow at 8.8% CAGR by 2030 - openPR.com
Porphyria Treatment Market Growth in Future Scope 2025-2032 - openPR.com
Protein Expression Market Forecast 2024-2031 | Growth & - openPR.com
Lateral Flow Assay Market Boosted by Point-of-Care Testing - openPR.com
Digital Pcr And Real Time Pcr Market Set to Witness Significant - openPR.com
Bio-Rad Laboratories B (BIO.B) Surges 11.58% Intraday: What's Fueling This Sharp Uptick? - AInvest
Cardiac Marker Testing Devices Market Is Booming So Rapidly - openPR.com
Bio Rad Laboratories Inc. Sees Spike in Bullish Option FlowDaily Chart Pattern Stock Forecast Shows Bullish Setup - metal.it
How does Bio Rad Laboratories Inc. compare to its industry peersIdentify undervalued stocks ready to soar - Jammu Links News
What drives Bio Rad Laboratories Inc. stock priceConsistently high returns - Jammu Links News
What are the latest earnings results for Bio Rad Laboratories Inc.Accelerated investment success - Jammu Links News
What institutional investors are buying Bio Rad Laboratories Inc. stockAchieve rapid financial growth with expert help - Jammu Links News
What are analysts’ price targets for Bio Rad Laboratories Inc. in the next 12 monthsStrong return on investment - Jammu Links News
Bio-Rad raises 2025 life science guidance to flat to 1% growth and expands ddPCR portfolio following Stilla acquisition - MSN
Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? - 富途牛牛
Bio-Rad Laboratories’ Stock Jumps on Positive Q2 Performance - timothysykes.com
Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results - simplywall.st
Here's What Analysts Are Forecasting For Bio-Rad Laboratories, Inc. (NYSE:BIO) After Its Second-Quarter Results - Yahoo Finance
Is Bio Rad Laboratories Inc. a good long term investmentBreakout stock performance - Jammu Links News
Why is Bio Rad Laboratories Inc. stock attracting strong analyst attentionUnstoppable investment returns - Jammu Links News
Does Bio Rad Laboratories Inc. stock perform well during market downturnsBuild your wealth with consistent stock growth - Jammu Links News
When is Bio Rad Laboratories Inc. stock expected to show significant growthIdentify safe investments with exceptional yields - Jammu Links News
How volatile is Bio Rad Laboratories Inc. stock compared to the marketIdentify winners with top-tier analysis - Jammu Links News
Is Bio Rad Laboratories Inc. a growth stock or a value stockDiscover top stock picks for aggressive growth - Jammu Links News
How does Bio Rad Laboratories Inc. generate profit in a changing economyPhenomenal investment performance - Jammu Links News
Bio-Rad Laboratories: A Case for Long-Term Growth in the Life Sciences Sector - AInvest
Bio-Rad Laboratories Surges as Analysts Boost Price Targets - StocksToTrade
Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - Yahoo Finance
Bio-Rad Laboratories Second Quarter 2025 Earnings: EPS: US$11.67 (vs US$76.26 loss in 2Q 2024) - Yahoo Finance
Bio-Rad (BIO) Beats Q2 Earnings Estimates, Boosts Outlook With Strong Revenue Growth - Insider Monkey
Bio-Rad Q2 2025 net sales up 2.1% to USD 651.6M - Medical Buyer
Bio-Rad Reports Q2 2025 Financial Results - The Globe and Mail
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings - 富途牛牛
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025 - BioSpace
Bio-Rad Laboratories (BIO) Soars 18% on Regulatory Shifts and Sector Momentum – What’s Fueling the Surge? - AInvest
RBC Capital Raises Price Target for Bio-Rad Laboratories (BIO) t - GuruFocus
Bio-Rad Laboratories (BIO) Receives Updated Price Target from We - GuruFocus
Bio-Rad Laboratories: Wells Fargo Keeps Equal-Weight Rating, Raises PT to $265. - AInvest
Bio-Rad Laboratories shares surge 17.67% intraday after strong Q2 earnings and Stilla Technologies acquisition. - AInvest
Wells Fargo Raises Price Target for Bio-Rad (BIO) - GuruFocus
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2025 Earnings Call Transcript - Insider Monkey
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025 | About UsThe San Diego Union-Tribune - FinancialContent
Tide Fluor Dyes Market Set To Explode Growth by 2025-2032 | Thermo - openPR.com
Bio-Rad Q2 2025 slides: Revenue grows 2.1% despite margin pressure By Investing.com - Investing.com South Africa
Bio-Rad Q2 2025 slides: Revenue grows 2.1% despite margin pressure - Investing.com Nigeria
Bio-Rad Laboratories Q2 Financial Turnaround: $317.8 Million Net IncomeNews and Statistics - IndexBox
Bio-Rad Laboratories Q2 2025 Earnings Call Transcript - MarketBeat
11 Best Medical Stocks to Buy According to Analysts - Insider Monkey
Bio-Rad Laboratories Inc (BIO) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges - Yahoo Finance
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):